The tweet was deleted by the author.
But we saved everything 🙂.
REGENXBIO is stepping up its commercial operations with the active involvement of Paul Oyefesobi on its commercial team.
Oyefesobi is playing a central role in ensuring that the company is prepared to deliver future therapies to patients, focusing on strategic planning and execution for upcoming product launches. The company aims to accelerate its readiness and optimize patient access as it gears up for the introduction of new therapeutic offerings. Details about specific initiatives or products have not been disclosed. Details are being clarified.
REGENXBIO recently participated in a CureDuchenne community event aimed at supporting the development of new therapies for Duchenne. The company has also expanded its AFFINITY DUCHENNE study, highlighting ongoing efforts to provide patient and family support throughout clinical development. Both initiatives reflect REGENXBIO's ongoing engagement with the patient community ahead of future product launches.